- Zacks•8 days ago
Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).
- Business Wire•8 days ago
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Puma Biotechnology, Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
- Business Wire•11 days agoPuma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
Puma Biotechnology, Inc. , a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 as a single agent in patients with solid tumors who have an activating HER2 mutation .
PBYI : Summary for Puma Biotechnology Inc - Yahoo Finance
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||33.90 x 2000|
|Ask||38.00 x 200|
|Day's Range||33.30 - 35.65|
|52 Week Range||19.74 - 73.27|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|